Barnes D M, Skinner L G, Ribeiro G G
Br J Cancer. 1979 Dec;40(6):862-5. doi: 10.1038/bjc.1979.277.
In a group of 74 patients with advanced metastatic breast cancer, 57% of those with cytoplasmic oestrogen receptor activity in their tumours (REC+) showed a clinical response to endocrine therapy. Of 51 patients whose tumour was assayed for both REC and cytoplasmic progesterone (RPC) activity, 9/12 patients with REC+ RPC+ tumours responded to hormone treatment, whereas only 3/30 patients with REC-RPC-tumours had a clinical response. In a group of 19 patients in whom nuclear oestrogen receptor (REN) was also estimated in the pellets from tumour-tissue homogenates, 5/6 with tumours positive for all 3 receptors showed a clinical response. None of the 9 patients with triply negative tumours responded. Addition of the REN assay appears to reinforce the greater precision of prediction when RPC as well as REC are estimated in breast tumours.
在一组74例晚期转移性乳腺癌患者中，肿瘤具有细胞质雌激素受体活性（REC+）的患者中有57%对内分泌治疗有临床反应。在51例肿瘤同时检测了REC和细胞质孕激素（RPC）活性的患者中，9/12例REC+ RPC+肿瘤患者对激素治疗有反应，而REC-RPC-肿瘤患者中只有3/30例有临床反应。在一组19例患者中，还对肿瘤组织匀浆沉淀物中的细胞核雌激素受体（REN）进行了评估，6例所有3种受体均为阳性的肿瘤患者中有5例有临床反应。9例三重阴性肿瘤患者均无反应。当在乳腺肿瘤中同时评估RPC和REC时，增加REN检测似乎能提高预测的准确性。
